ArticleHepatology communications2017
Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma.
Article in Hepatology communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Changing etiological spectrum of cirrhosis in China: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver.Hepatology international · 2023Guideline
- HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis.Journal of hepatology · 2022Pooled it
- The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationGuideline
- RESONANCE: Protocol for a Nationwide Cohort Study of Chronic Liver Diseases Using the French National Health Data System.JMIR research protocols · 2026Article
- Automatic phenotyping of emergency department patients with incidental hepatic steatosis: A machine learning clustering analysis.The American journal of emergency medicine · 2026Article
- The Prevalence and Risk Factors for at-Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care.Alimentary pharmacology & therapeutics · 2026Article
- A reasonably likely surrogate endpoint for metabolic dysfunction-associated steatohepatitis.Nature medicine · 2026Article
- Development of an AI algorithm for early identification of MASLD in the electronic health record.Hepatology communications · 2025Article
- Call to action: integrating steatotic liver disease into public health strategies in Canada.Lancet regional health. Americas · 2025Review
- Article
- Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary.The Medical journal of Australia · 2025Article
- Health disparities in cirrhosis care and liver transplantation.Nature reviews. Gastroenterology & hepatology · 2025Review
- FIB-4: A screening tool for advanced liver fibrosis in a cohort of subjects participating in a primary care weight-loss program.PloS one · 2025Article
- Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease.Biomedicines · 2025Article
- NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Current diabetes reports · 2024Review
- Early screening for chronic liver disease: impact of a FIB-4 first integrated care pathway to identify patients with significant fibrosis.Scientific reports · 2024Article
- An Australian Community-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Care Pathway for People with Type 2 Diabetes: Barriers and Considerations.Patient preference and adherence · 2024Article
- Predictive Algorithm for Hepatic Steatosis Detection Using Elastography Data in the Veterans Affairs Electronic Health Records.Digestive diseases and sciences · 2023Article
- A salivary biomarker panel to detect liver cirrhosis.iScience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Determination of cirrhosis in nonalcoholic fatty liver disease (NAFLD) is important as it alters prognosis and management. We aimed to examine whether cirrhosis was diagnosed incidentally or intentionally in patients with NAFLD. We reviewed 100 patients with NAFLD cirrhosis to determine mode of cirrhosis diagnosis (incidental or by intent), severity of liver disease at diagnosis, diagnostician, and previous clinical imaging or laboratory evidence of unrecognized cirrhosis. The majority (66/100) of patients with NAFLD cirrhosis were diagnosed incidentally, with the majority of these (74%) diagnosed with NAFLD simultaneously. Those with incidental cirrhosis diagnoses had more deranged platelet and international normalized ratio levels (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.